Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 5821 AL 5835

Novel disease-modifying therapies for Alzheimer's disease

Jiang T, Yu JT, Tan L.

J Alzheimers Dis. 2012;31(3):475-92. doi: 10.3233/JAD-2012-120640.

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study

Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H, Iwamoto T.

Geriatr Gerontol Int. 2013 Jan;13(1):90-7. doi: 10.1111/j.1447-0594.2012.00866.x. Epub 2012 Jun 4.

Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy

Zheng H, Fridkin M, Youdim MB.

Curr Drug Targets. 2012 Jul;13(8):1089-106. doi: 10.2174/138945012802009026.

Synaptic changes in Alzheimer's disease and its models

Pozueta J, Lefort R, Shelanski ML.

Neuroscience. 2013 Oct 22;251:51-65. doi: 10.1016/j.neuroscience.2012.05.050. Epub 2012 Jun 9.

Pleiotropic protective effects of phytochemicals in Alzheimer's disease

Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G.

Oxid Med Cell Longev. 2012;2012:386527. doi: 10.1155/2012/386527. Epub 2012 May 28.

Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease

Ooi L, Sidhu K, Poljak A, Sutherland G, O'Connor MD, Sachdev P, Münch G.

J Neural Transm (Vienna). 2013 Jan;120(1):103-11. doi: 10.1007/s00702-012-0839-2. Epub 2012 Jun 13.

The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation

Anand A, Banik A, Thakur K, Masters CL.

Curr Alzheimer Res. 2012 Nov;9(9):1010-29. doi: 10.2174/156720512803569055.

Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria

Schaffer S, Asseburg H, Kuntz S, Muller WE, Eckert GP.

Mol Neurobiol. 2012 Aug;46(1):161-78. doi: 10.1007/s12035-012-8282-9. Epub 2012 Jun 17.

Copper and oxidative stress in the pathogenesis of Alzheimer's disease

Eskici G, Axelsen PH.

Biochemistry. 2012 Aug 14;51(32):6289-311. doi: 10.1021/bi3006169. Epub 2012 Jul 31.

Colombia at the centre of preclinical AD research

Lancet Neurol. 2012 Jul;11(7):567. doi: 10.1016/S1474-4422(12)70144-8.

γ-Secretase modulator in Alzheimer's disease: shifting the end

Xia W, Wong ST, Hanlon E, Morin P.

J Alzheimers Dis. 2012;31(4):685-96. doi: 10.3233/JAD-2012-120751.

A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial

Molloy DW, Standish TI, Zhou Q, Guyatt G; DARAD Study Group.

Int J Geriatr Psychiatry. 2013 May;28(5):463-70. doi: 10.1002/gps.3846. Epub 2012 Jun 21.

Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia

Allegri RF, Guekht A.

Drugs Today (Barc). 2012 Apr;48 Suppl A:25-41. doi: 10.1358/dot.2012.48(Suppl.A).1739721.

The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery

Sharma HS, Castellani RJ, Smith MA, Sharma A.

Int Rev Neurobiol. 2012;102:47-90. doi: 10.1016/B978-0-12-386986-9.00003-X.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias